In phase 2 trial, novel therapy significantly reduced triglyceride levels
A phase 2b clinical trial led by Mass General Brigham Heart and Vascular Institute researchers shows that a monoclonal antibody therapy called MAR001 can significantly reduce triglyceride levels within 12 weeks for patients with high triglyceride levels. Their results are published in the New England Journal of Medicine and were presented simultaneously at the American Heart Association's annual…
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
Two-year study will examine how gender-affirming hormone therapy affects energy use and blood vessel function
United Kingdom
-
Study challenges long-held fears about overactive bladder drugs and dementia
United Kingdom
-
Stanford study challenges long-held dogma on causes of concussions
United Kingdom
-
New monoclonal antibody therapy significantly lowers patient triglyceride levels
United Kingdom
-
Cluster headache linked to pronounced levels of burnout symptoms
United Kingdom
-
Could a daily supplement keep blood vessels healthier as we age?
United Kingdom
-
Why obesity affects males and females differently
United Kingdom
-
Your brain may map emotional concepts onto a hexagonal grid, new study suggests
United Kingdom